Skip to main content

Lung Transplant Rejection

2
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
macitentanPhase 41 trial
Active Trials
NCT02893176Withdrawn0Est. Sep 2019
Meiji Seika Pharma
Meiji Seika PharmaJapan - Tokyo
1 program
1
BelumosudilPhase 3
Paragonix Technologies
1 program
Breathe sampleN/A
Breathe BioMedical
Breathe BioMedicalMA - Cambridge
1 program
Breathe sampleN/A1 trial
Active Trials
NCT06309628Terminated35Est. May 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Longitudinal Study of Cell Free DNA in Lung TransplantN/A1 trial
Active Trials
NCT04234919Completed24Est. Nov 2021
Natera
NateraAUSTIN, TX
1 program
ProsperaN/A1 trial
Active Trials
NCT05170425Active Not Recruiting154Est. May 2027
Bristol Myers Squibb
1 program
BelataceptPHASE_21 trial
Active Trials
NCT03388008Completed27Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Angeles Therapeuticsmacitentan
Bristol Myers SquibbBelatacept
Breathe BioMedicalBreathe sample
NateraProspera
Colorado TherapeuticsLongitudinal Study of Cell Free DNA in Lung Transplant

Clinical Trials (5)

Total enrollment: 240 patients across 5 trials

NCT02893176Angeles Therapeuticsmacitentan

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

Start: Sep 2016Est. completion: Sep 20190
Phase 4Withdrawn
NCT03388008Bristol Myers SquibbBelatacept

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

Start: Dec 2019Est. completion: Aug 202227 patients
Phase 2Completed
NCT06309628Breathe BioMedicalBreathe sample

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy

Start: Sep 2023Est. completion: May 202535 patients
N/ATerminated
NCT05170425NateraProspera

LAMBDA 002 (Lung Registry) Study

Start: Nov 2022Est. completion: May 2027154 patients
N/AActive Not Recruiting
NCT04234919Colorado TherapeuticsLongitudinal Study of Cell Free DNA in Lung Transplant

Longitudinal Study of Cell Free DNA in Lung Transplant

Start: Mar 2020Est. completion: Nov 202124 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.